Intercept Pharmaceuticals Profit Margin

Intercept Pharmaceuticals (ICPT) currently reports a profit margin of -20.49% as of September 2023. That compares with 62.47% in the prior-year period — down 132.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Intercept Pharmaceuticals's profit margin history and peer comparisons.

Intercept Pharmaceuticals's profit margin decreased from 62.47% to -20.49% — a 132.8% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intercept Pharmaceuticals's profit margin of -20.49% is lower than the Healthcare sector average of 13.89%. That is roughly 247.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Intercept Pharmaceuticals's current -20.49% should be judged against Healthcare norms (sector average: 13.89%) and against ICPT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -20.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Intercept Pharmaceuticals, and consider following ICPT for alerts when major investors trade the stock.